Neuropathy Composition Synergy CB2 Receptor Pain Relief

The patent applies the composite materials principle by formulating a multi-component nutraceutical composition containing palmitoylethanolamide, α-lipoic acid, vitamin D3, and β-caryophyllene. This composite approach combines substances with complementary mechanisms of action: palmitoylethanolamide modulates the endocannabinoid system and PPAR-α receptors, α-lipoic acid provides antioxidant support and nerve regeneration, vitamin D3 addresses neurotrophic factors, and β-caryophyllene acts on CB2 receptors. The synergistic interaction of these components achieves superior analgesic efficacy for neuropathic pain while maintaining a favorable safety profile without the harmful side effects associated with traditional analgesics.

The patent applies the merging principle by consolidating multiple therapeutic agents into a single integrated nutraceutical formulation. Instead of requiring separate administration of antidepressants, antiepileptics, or opioids, the composition combines palmitoylethanolamide, α-lipoic acid, vitamin D3, and β-caryophyllene in one product. This unified approach simplifies the treatment regimen, improves patient compliance, and enables synergistic interactions between components while avoiding the cumulative side effects of polypharmacy.

The patent applies the parameter changes principle by shifting from conventional pharmacological parameters (opioid receptors, monoamine reuptake inhibition) to alternative biological parameters involving the endocannabinoid system, PPAR-α receptors, and antioxidant pathways. By utilizing naturally occurring substances like palmitoylethanolamide and α-lipoic acid that act through these different mechanisms, the composition achieves effective neuropathic pain control through novel pathways not engaged by traditional analgesics, thereby improving effectiveness while maintaining ease of manufacture as a nutraceutical product.